Issued on exercise of
Exchange Rights 137,733 1,009,437 - -
Exchange Rights
expired unexercised - - 242,500 -
Expiry of share
purchase warrants - - 486,615 -
Issued on acquisition
of ENI, net 2,109,479 10,727,317 - -
Issued to acquire
patent portfolio 46,055 286,000 - -
Cancellation of shares
issued to ENI (98,328) (559,475) 559,475 -
Stock options exercised 2,545 13,054 - (5,038)
Stock options expired - - 369,431 (369,431)
Stock-based compensation
expense - - - 405,699
Net loss for the year - - - -
-------------------------------------------------------------------------
Balance, June 30,
2006 17,494,269 99,563,853 4,469,987 774,858
-------------------------------------------------------------------------
Adjustment to opening
retained earnings for
change in accounting
policy related to
research inventory - - - -
Stock options exercised 63,654 601,571 - (221,177)
Stock options expired - - 17,765 (17,765)
Stock-based
compensation expense - - - 1,002,480
Issued pursuant to
private placement,
net 2,986,867 23,964,751 - -
Issued on acquisition
of NeuroMedix Inc.,
net 685,951 9,858,143 - -
Net loss for the year
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2007 PR Newswire. All rights reserved |